A retrospective analysis of second-line chemotherapy in patients with advanced gastric cancer
By Sang Hoon Ji, Do Hyoung Lim, Seong Yoon Yi, Hyo Song Kim, Hyun Jung Jun, Kyoung Ha Kim, Myung Hee Chang, Min Jae Park, Ji Eun Uhm, Jeeyun Lee, Se Hoon Park, Joon Oh Park, Young Suk Park, Ho Yeong Lim and Won Ki Kang
(2006). al.: HER-2/neu amplification is an independent prognostic factor in gastric cancer. Digestive diseases and sciences
(2006). Anemia is the strongest prognostic factor for outcomes of 5-fluorouracil-based first-line chemotherapy in patients with advanced gastric cancer. Cancer Chemother Pharmacol
(2006). DB: Quality of life in patients with advanced gastric cancer treated with second-line chemotherapy. Cancer Chemother Pharmacol
(2004). Docetaxel plus cisplatin as secondline therapy in metastatic or recurrent advanced gastric cancer progressing on 5-fluorouracil-based regimen.
(2000). et al.: New guidelines to evaluate the response to treatment in solid tumors.
(2007). Ferraraccio F: Epidermal growth factor receptor (EGFR) expression is associated with a worse prognosis in gastric cancer patients undergoing curative surgery. World journal of surgery
(2008). Galizia G: Expression of vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) is an independent prognostic indicator of worse outcome in gastric cancer patients. Annals of surgical oncology
(2008). Impacts of excision repair cross-complementing gene 1 (ERCC1), dihydropyrimidine dehydrogenase, and epidermal growth factor receptor on the outcomes of patients with advanced gastric cancer.
(2002). JG: Annual report of the Korean central cancer registry program 2000. Cancer Res Treat
(2008). Mitomycin C plus S-1 as second-line therapy in patients with advanced gastric cancer: a noncomparative phase II study. Anticancer Drugs
(2002). Ohtsu A: The role of chemotherapy in the current treatment of gastric cancer. Gastric Cancer
(2004). PJ: Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer – pooled analysis from three multicenter, randomized, controlled trials using individual patient data.
(2007). Prognostic model to predict survival following firstline chemotherapy in patients with metastatic gastric adenocarcinoma. Ann Oncol
(1995). Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer.
(1997). Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol
(2005). Review of second-line chemotherapy for advanced gastric adenocarcinoma. Clin Oncol (R Coll Radiol)
(2005). Salvage chemotherapy with irinotecan and cisplatin in patients with metastatic gastric cancer failing both 5-fluorouracil and taxanes. Anticancer Drugs